Press Releases Press Releases Year None2022202120202019201820172016201520142013201120102009200820072005 August 9, 2022 Intra-Cellular Therapies Reports Second Quarter 2022 Financial Results and Provides Corporate Update PDF Version August 2, 2022 Intra-Cellular Therapies to Host Second Quarter 2022 Financial Results Conference Call and Webcast PDF Version June 13, 2022 Intra-Cellular Therapies Highlights Lumateperone Bipolar Depression Data Presentations at the 2022 International Society for Bipolar Disorders (ISBD) Experience PDF Version May 10, 2022 Intra-Cellular Therapies Reports First Quarter 2022 Financial Results and Provides Corporate Update PDF Version May 3, 2022 Intra-Cellular Therapies to Host First Quarter 2022 Financial Results Conference Call and Webcast PDF Version April 25, 2022 Intra-Cellular Therapies Announces FDA Approval of New Dosage Strengths for CAPLYTA® (lumateperone) for Specific Patient Populations PDF Version April 21, 2022 Intra-Cellular Therapies Announces Appointment of E. Rene Salas to Board of Directors PDF Version April 5, 2022 Intra-Cellular Therapies to Present at the 21st Annual Needham Virtual Healthcare Conference PDF Version March 1, 2022 Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update PDF Version February 22, 2022 Intra-Cellular Therapies to Host Fourth Quarter and Full Year 2021 Financial Results Conference Call and Webcast PDF Version Pagination Current page 1 Page 2 Next page next › Last page last »
August 9, 2022 Intra-Cellular Therapies Reports Second Quarter 2022 Financial Results and Provides Corporate Update PDF Version
August 2, 2022 Intra-Cellular Therapies to Host Second Quarter 2022 Financial Results Conference Call and Webcast PDF Version
June 13, 2022 Intra-Cellular Therapies Highlights Lumateperone Bipolar Depression Data Presentations at the 2022 International Society for Bipolar Disorders (ISBD) Experience PDF Version
May 10, 2022 Intra-Cellular Therapies Reports First Quarter 2022 Financial Results and Provides Corporate Update PDF Version
May 3, 2022 Intra-Cellular Therapies to Host First Quarter 2022 Financial Results Conference Call and Webcast PDF Version
April 25, 2022 Intra-Cellular Therapies Announces FDA Approval of New Dosage Strengths for CAPLYTA® (lumateperone) for Specific Patient Populations PDF Version
April 21, 2022 Intra-Cellular Therapies Announces Appointment of E. Rene Salas to Board of Directors PDF Version
April 5, 2022 Intra-Cellular Therapies to Present at the 21st Annual Needham Virtual Healthcare Conference PDF Version
March 1, 2022 Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update PDF Version
February 22, 2022 Intra-Cellular Therapies to Host Fourth Quarter and Full Year 2021 Financial Results Conference Call and Webcast PDF Version
